SIETES :: 93091 citas

Resultados de la búsqueda por RIESGO CARDIOVASCULAR REFINAR BÚSQUEDA

1.

Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in covid-19. N Engl J Med 2020;382:18 de junio. [Ref.ID 103602]

2.

Jefferson T, Demasi M, Doshi P. Statins for primary prevention: what is the regulator’s role?. BMJ Evidence-Based Medicine 2020:marzo. [Ref.ID 103575]

3.

Simon TG, Duberg A-S, Aleman S, Chung RT, Chan AT, Ludvigsson JF. Association of aspirin with hepatocellular carcinoma and liver-related mortality. N Engl J Med 2020;382:12 de marzo. [Ref.ID 103565]

4.

Maihofer AX, Shadyab AH, Wild RA, LaCroix AZ. Associations between serum levels of cholesterol and survival to age 90 in postmenopausal women. J Am Geriatr Soc 2020;68:febrero. [Ref.ID 103544]

5.

Herman AO. FDA approves new cholesterol-lowering drug. Journal Watch 2020:24 de febrero. [Ref.ID 103538]

6.

Wallach JD, Wang K, Zhang AD, Cheng D, Grossetta Nardini HK, Lin H, Bracken MB, Desai M, Krumholz HM, Ross JS. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. BMJ 2020;368:5 de febrero. [Ref.ID 103514]

7.

McEvoy JB, Daya N, Rahman F, Hoogeveen RC, Blumenthal RS, Shah AM, Ballantyne CM, Coresh J, Selvin E. Association of isolated diastolic hypertension as defined by the 2017 ACC/AHA blood pressure guideline with incident cardiovascular outcomes. JAMA 2020;323:28 de enero. [Ref.ID 103512]

8.

Saragiotto BT, Abdel Shaheed C, Maher CG. Paracetamol for pain in adults. BMJ 2020;367:17 de enero. [Ref.ID 103510]

9.

Anónimo. FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groups. U.S. Food and Drug Administration 2019:13 de diciembre. [Ref.ID 103231]

10.

Shah R, Khan B, Latham SB, Khan SA, Rao SB. A meta-analysis of aspirin for the primary prevention of cardiovascular diseases in the context of contemporary preventive strategies. Am J Med 2019:31 de mayo. [Ref.ID 103205]

11.

Hermida RC, Crespo JJ, Domínguez-Sardina M, et al.. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J 2019:septiembre. [Ref.ID 103201]

12.

Byrne P, Cullinan J, Smith S. Statins for primary prevention of cardiovascular disease. BMJ 2019;367:16 de octubre. [Ref.ID 103197]

13.

Perkovic V, Jardine MJ, Neal BBompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, for the CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:13 de junio. [Ref.ID 103155]

14.

Xie Y, Bowe B, Yan Y, Xian H, Li T. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ 2019;365:30 de mayo. [Ref.ID 103138]

15.

Ma H, Li X, Sun D, Zhou T, Ley SH, Gustat J, Heianza Y, Qi L. Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank. BMJ 2019;365:l1628. [Ref.ID 103121]

16.

Akyea RK, Kai J, Qureshi N, Iyen B, Weng SF. Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease. Heart 2019:15 de abril. [Ref.ID 103087]

17.

Musso G, Gambino R, Cassader M, Paschetta E. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2019;365:9 de abril. [Ref.ID 103085]

18.

Anónimo. FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture. U.S. Food and Drug Administration 2019:9 de abril. [Ref.ID 103084]

19.

Gorelik E, Masarwa R, Perlman A, Rotshild V, Abbasi M, Muszkat M, Matok I. Fluoroquinolones and cardiovascular risk: a systematic review, meta-analysis and network meta-analysis. Drug Saf 2019;42:abril. [Ref.ID 103082]

20.

Zhong VW, Van Horn L, Cornelis MC, Wilkins JT, Ning H, Carnethon MR, Greenland P, Mentz RJ, Tucker KL, Zhao L, Norwood AF, Lloyd-Jones DM, Allen NB. Associations of dietary cholesterol or egg consumption with incident cardiovascular disease and mortality. JAMA 2019;321:19 de marzo. [Ref.ID 103072]